Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolb, H. J.
Right arrow Articles by Wilmanns, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolb, H. J.
Right arrow Articles by Wilmanns, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

HJ Kolb, J Mittermuller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim and W Wilmanns

Medizinische Klinik III, Klinikum Grosshadern, Universtat Munchen, Germany.

Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91 weeks after treatment. In two patients graft-versus-host disease developed and was treated by immunosuppression. These results are an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras.

Volume 76, Issue 12, pp. 2462-2465, 12/15/1990
Copyright © 1990 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. J. Wu and J. Ritz
Revealing Tumor Immunity after Hematopoietic Stem Cell Transplantation
Clin. Cancer Res., July 15, 2009; 15(14): 4515 - 4517.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Kamiryo, M. Eto, H. Yamada, T. Yajima, M. Harano, A. Takeuchi, K. Tatsugami, M. Hamaguchi, S. Naito, and Y. Yoshikai
Donor CD4 T Cells Are Critical in Allogeneic Stem Cell Transplantation against Murine Solid Tumor
Cancer Res., June 15, 2009; 69(12): 5151 - 5158.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Nardi, O. Naveiras, M. Azam, and G. Q. Daley
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines
Blood, April 16, 2009; 113(16): 3813 - 3820.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. Haniffa, F. Ginhoux, X.-N. Wang, V. Bigley, M. Abel, I. Dimmick, S. Bullock, M. Grisotto, T. Booth, P. Taub, et al.
Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation
J. Exp. Med., February 16, 2009; 206(2): 371 - 385.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. T. van der Veken, M. Coccoris, E. Swart, J. H. F. Falkenburg, T. N. Schumacher, and M. H. M. Heemskerk
{alpha}{beta} T Cell Receptor Transfer to {gamma}{delta} T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo
J. Immunol., January 1, 2009; 182(1): 164 - 170.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
A. Mackensen
Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy
ASCO Educational Book, January 1, 2009; 2009(1): 521 - 524.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood, December 1, 2008; 112(12): 4371 - 4383.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. Griffioen, H.M. E. van Egmond, H. Barnby-Porritt, M. A.W.G. van der Hoorn, R. S. Hagedoorn, M. G.D. Kester, N. Schwabe, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk
Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application
Haematologica, October 1, 2008; 93(10): 1535 - 1543.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al.
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Blood, June 15, 2008; 111(12): 5530 - 5536.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al.
Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor
Clin. Cancer Res., May 1, 2008; 14(9): 2833 - 2840.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg
Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity
PNAS, March 11, 2008; 105(10): 3837 - 3842.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. Conrad, M. Remberger, K. Cederlund, O. Ringden, and L. Barkholt
A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors
Haematologica, February 1, 2008; 93(2): 265 - 272.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al.
Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol., January 20, 2008; 26(3): 455 - 462.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
D.-P. Chen, C.-P. Tseng, S.-H. Tsai, T.-L. Wu, P.-Y. Chang, and C.-F. Sun
Systematic Analysis of Stutters to Enhance the Accuracy of Chimerism Testing
Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 264 - 272.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
S. Mackinnon
Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation
ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
Y. Yoshida, T. Hirano, G. Son, Y. Iimuro, T. Imado, T. Iwasaki, and J. Fujimoto
Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease
Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1114 - G1123.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Schmid, M. Labopin, A. Nagler, M. Bornhauser, J. Finke, A. Fassas, L. Volin, G. Gurman, J. Maertens, P. Bordigoni, et al.
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
J. Clin. Oncol., November 1, 2007; 25(31): 4938 - 4945.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Scheich, J. Duyster, C. Peschel, and H. Bernhard
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens
Blood, October 1, 2007; 110(7): 2556 - 2560.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, et al.
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
Blood, October 1, 2007; 110(7): 2761 - 2763.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al.
Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood, June 1, 2007; 109(11): 4698 - 4707.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Blood, May 15, 2007; 109(10): 4564 - 4574.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman
Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo
J. Immunol., February 15, 2007; 178(4): 2028 - 2037.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Eto, M. Harano, K. Tatsugami, M. Harada, Y. Kamiryo, K. Kiyoshima, M. Hamaguchi, M. Tsuneyoshi, Y. Yoshikai, and S. Naito
Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease
Clin. Cancer Res., February 1, 2007; 13(3): 1029 - 1035.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. H. Antin
Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2
Hematology, January 1, 2007; 2007(1): 47 - 54.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
J. Clin. Oncol., November 1, 2006; 24(31): 5060 - 5069.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
J. Aschan
Allogeneic haematopoietic stem cell transplantation: current status and future outlook
Br. Med. Bull., October 5, 2006; (2006) ldl005v2.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. L. Porter
RIC for MDS: the glass is half full
Blood, August 1, 2006; 108(3): 780 - 781.
[Full Text] [PDF]


Home page
BloodHome page
E. H. Slager, M. W. Honders, E. D. van der Meijden, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, M. G. D. Kester, I. Jedema, W. A. E. Marijt, M. R. Schaafsma, R. Willemze, et al.
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer
Blood, June 15, 2006; 107(12): 4954 - 4960.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. J. Mauro and R. T. Maziarz
Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?
Mayo Clin. Proc., March 1, 2006; 81(3): 404 - 416.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. F. Apperley
Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 226 - 232.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. M. Kloosterboer, S. A. P. van Luxemburg-Heijs, R. A. van Soest, H. M. E. van Egmond, R. Willemze, and J. H. F. Falkenburg
Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia
Blood, December 1, 2005; 106(12): 3955 - 3957.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito
Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice
Cancer Res., November 1, 2005; 65(21): 10032 - 10040.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S.-A. Xue, L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, et al.
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells
Blood, November 1, 2005; 106(9): 3062 - 3067.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
C. Lotze, F. Schuler, W. H. Kruger, C. Hirt, M. Kirsch, S. Vogelgesang, C. A. Schmidt, and G. Dolken
Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: Case study
Neuro-oncol, October 1, 2005; 7(4): 508 - 510.
[Abstract] [PDF]


Home page
BloodHome page
J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt
Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia
Blood, August 1, 2005; 106(3): 938 - 945.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J. Wu, M. Biernacki, J. L. Kutok, S. Rogers, L. Chen, X.-F. Yang, R. J. Soiffer, and J. Ritz
Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells
Clin. Cancer Res., June 15, 2005; 11(12): 4504 - 4511.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. W. N. Deininger
Adoptive immunotherapy of murine CML: navigating between Scylla and Charybdis
Blood, December 15, 2004; 104(13): 3843 - 3843.
[Full Text] [PDF]


Home page
BloodHome page
D. S. Krause and R. A. Van Etten
Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model
Blood, December 15, 2004; 104(13): 4236 - 4244.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Takahashi and R. W. Childs
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6353S - 6359S.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. J. DeAngelo, E. P. Hochberg, E. P. Alyea, J. Longtine, S. Lee, I. Galinsky, B. Parekkedon, J. Ritz, J. H. Antin, R. M. Stone, et al.
Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft-versus-Host Disease
Clin. Cancer Res., August 1, 2004; 10(15): 5065 - 5071.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Bader, H. Kreyenberg, W. Hoelle, G. Dueckers, R. Handgretinger, P. Lang, B. Kremens, D. Dilloo, K.-W. Sykora, M. Schrappe, et al.
Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?
J. Clin. Oncol., May 1, 2004; 22(9): 1696 - 1705.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. H.M. Heemskerk, M. Hoogeboom, R. Hagedoorn, M. G.D. Kester, R. Willemze, and J.H. F. Falkenburg
Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer
J. Exp. Med., April 5, 2004; 199(7): 885 - 894.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. W. Childs
Evolving trends in hematopoietic cell transplantation for solid tumors: tempering enthusiasm with clinical reality
Ann. Onc., April 1, 2004; 15(4): 543 - 544.
[Full Text] [PDF]


Home page
JCOHome page
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. S. Peggs, K. Thomson, D. P. Hart, J. Geary, E. C. Morris, K. Yong, A. H. Goldstone, D. C. Linch, and S. Mackinnon
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
Blood, February 15, 2004; 103(4): 1548 - 1556.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel
Graft-versus-leukemia reactions in allogeneic chimeras
Blood, February 1, 2004; 103(3): 767 - 776.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. A. Bethge, U. Hegenbart, M. J. Stuart, B. E. Storer, M. B. Maris, M. E. D. Flowers, D. G. Maloney, T. Chauncey, B. Bruno, E. Agura, et al.
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
Blood, February 1, 2004; 103(3): 790 - 795.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Tamura, H. J. Kong, C. Tunyaplin, H. Tsujimura, K. Calame, and K. Ozato
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells
Blood, December 15, 2003; 102(13): 4547 - 4554.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. H. M. Heemskerk, M. Hoogeboom, R. A. de Paus, M. G. D. Kester, M. A. W. G. van der Hoorn, E. Goulmy, R. Willemze, and J. H. F. Falkenburg
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region
Blood, November 15, 2003; 102(10): 3530 - 3540.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. T. Ueno, Y. C. Cheng, G. Rondon, N. M. Tannir, J. L. Gajewski, D. R. Couriel, C. Hosing, M. J. de Lima, P. Anderlini, I. F. Khouri, et al.
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Blood, November 15, 2003; 102(10): 3829 - 3836.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. H. Antin
A 41-Year-Old Woman With Chronic Myelogenous Leukemia
JAMA, August 27, 2003; 290(8): 1083 - 1090.
[Full Text] [PDF]


Home page
Ann OncolHome page
M. Renga, P. Pedrazzoli, and S. Siena
Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors
Ann. Onc., August 1, 2003; 14(8): 1177 - 1184.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer
Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions
Blood, July 15, 2003; 102(2): 740 - 748.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Weber, C. Lange, W. Gunther, M. Franz, E. Kremmer, and H.-J. Kolb
Minor Histocompatibility Antigens on Canine Hemopoietic Progenitor Cells
J. Immunol., June 15, 2003; 170(12): 5861 - 5868.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
W. A. E. Marijt, M. H. M. Heemskerk, F. M. Kloosterboer, E. Goulmy, M. G. D. Kester, M. A. W. G. van der Hoorn, S. A. P. van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J. W. Drijfhout, et al.
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia
PNAS, March 4, 2003; 100(5): 2742 - 2747.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Worth, K. Rao, D. Webb, J. Chessells, J. Passmore, and P. Veys
Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion
Blood, March 1, 2003; 101(5): 1713 - 1714.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al.
Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
J. Clin. Oncol., February 15, 2003; 21(4): 615 - 623.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Or, M. Y. Shapira, I. Resnick, A. Amar, A. Ackerstein, S. Samuel, M. Aker, E. Naparstek, A. Nagler, and S. Slavin
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase
Blood, January 15, 2003; 101(2): 441 - 445.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Edinger, Y.-A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging
Blood, January 15, 2003; 101(2): 640 - 648.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. V. Melo, T. P. Hughes, and J. F. Apperley
Chronic Myeloid Leukemia
Hematology, January 1, 2003; 2003(1): 132 - 152.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs
Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors
Hematology, January 1, 2003; 2003(1): 372 - 397.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X.-F. Yang, C. J. Wu, L. Chen, E. P. Alyea, C. Canning, P. Kantoff, R. J. Soiffer, G. Dranoff, and J. Ritz
CML28 Is a Broadly Immunogenic Antigen, Which Is Overexpressed in Tumor Cells
Cancer Res., October 1, 2002; 62(19): 5517 - 5522.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Litvinova, S. Maury, O. Boyer, S. Bruel, L. Benard, G. Boisserie, D. Klatzmann, and J. L. Cohen
Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease
Blood, August 28, 2002; 100(6): 2020 - 2025.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer
Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants
Blood, August 13, 2002; 100(5): 1894 - 1902.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Y. Mapara, Y.-M. Kim, S.-P. Wang, R. Bronson, D. H. Sachs, and M. Sykes
Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells
Blood, August 13, 2002; 100(5): 1903 - 1909.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Guglielmi, W. Arcese, F. Dazzi, R. Brand, D. Bunjes, L. F. Verdonck, A. Schattenberg, H.-J. Kolb, P. Ljungman, A. Devergie, et al.
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
Blood, June 28, 2002; 100(2): 397 - 405.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Alizadeh, M. Bernard, B. Danic, C. Dauriac, B. Birebent, C. Lapart, T. Lamy, P.-Y. Le Prise, A. Beauplet, D. Bories, et al.
Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction
Blood, May 29, 2002; 99(12): 4618 - 4625.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Bregni, A. Dodero, J. Peccatori, A. Pescarollo, M. Bernardi, I. Sassi, C. Voena, A. Zaniboni, C. Bordignon, and P. Corradini
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer
Blood, May 13, 2002; 99(11): 4234 - 4236.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. J. Weisdorf, C. Anasetti, J. H. Antin, N. A. Kernan, C. Kollman, D. Snyder, E. Petersdorf, G. Nelson, and P. McGlave
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation
Blood, March 15, 2002; 99(6): 1971 - 1977.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Teshima, C. Liu, K. P. Lowler, G. Dranoff, and J. L. M. Ferrara
Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation
Cancer Res., February 1, 2002; 62(3): 796 - 800.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Chakraverty, K. Peggs, R. Chopra, D. W. Milligan, P. D. Kottaridis, S. Verfuerth, J. Geary, D. Thuraisundaram, K. Branson, S. Chakrabarti, et al.
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
Blood, February 1, 2002; 99(3): 1071 - 1078.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. M. Kang, M. de Witte, H. Malech, R. A. Morgan, S. Phang, C. Carter, S. F. Leitman, R. Childs, A. J. Barrett, R. Little, et al.
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome
Blood, January 15, 2002; 99(2): 698 - 701.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Corradini, C. Tarella, A. Olivieri, A. M. Gianni, C. Voena, F. Zallio, M. Ladetto, M. Falda, M. Lucesole, A. Dodero, et al.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies
Blood, January 1, 2002; 99(1): 75 - 82.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. P. Radich, T. Gooley, E. Bryant, T. Chauncey, R. Clift, L. Beppu, S. Edmands, M. E. D. Flowers, K. Kerkof, R. Nelson, et al.
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation
Blood, September 15, 2001; 98(6): 1701 - 1707.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Uzunel, J. Mattsson, M. Jaksch, M. Remberger, and O. Ringden
The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
Blood, September 15, 2001; 98(6): 1982 - 1985.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
U. M. Saarinen-Pihkala, G. Gustafsson, O. Ringden, C. Heilmann, A. Glomstein, G. Lonnerholm, J. Abrahamsson, A. N. Bekassy, H. Schroeder, and L. Mellander
No Disadvantage in Outcome of Using Matched Unrelated Donors as Compared With Matched Sibling Donors for Bone Marrow Transplantation in Children With Acute Lymphoblastic Leukemia in Second Remission
J. Clin. Oncol., July 15, 2001; 19(14): 3406 - 3414.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. A. McSweeney, D. Niederwieser, J. A. Shizuru, B. M. Sandmaier, A. J. Molina, D. G. Maloney, T. R. Chauncey, T. A. Gooley, U. Hegenbart, R. A. Nash, et al.
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Blood, June 1, 2001; 97(11): 3390 - 3400.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
B. J. Druker, C. L. Sawyers, R. Capdeville, J. M. Ford, M. Baccarani, and J. M. Goldman
Chronic Myelogenous Leukemia
Hematology, January 1, 2001; 2001(1): 87 - 112.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
R. F. Storb, R. Champlin, S. R. Riddell, M. Murata, S. Bryant, and E. H. Warren
Non-Myeloablative Transplants for Malignant Disease
Hematology, January 1, 2001; 2001(1): 375 - 391.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Dazzi, R. M. Szydlo, N. C. P. Cross, C. Craddock, J. Kaeda, E. Kanfer, K. Cwynarski, E. Olavarria, A. Yong, J. F. Apperley, et al.
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
Blood, October 15, 2000; 96(8): 2712 - 2716.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. D. Anderson Jr., S. Mori, S. Mann, C. A. Savary, and C. A. Mullen
Pretransplant Tumor Antigen-specific Immunization of Allogeneic Bone Marrow Transplant Donors Enhances Graft-versus-Tumor Activity without Exacerbation of Graft-versus-Host Disease
Cancer Res., October 1, 2000; 60(20): 5797 - 5802.
[Abstract] [Full Text]


Home page
BloodHome page
P. D. Kottaridis, D. W. Milligan, R. Chopra, R. K. Chakraverty, S. Chakrabarti, S. Robinson, K. Peggs, S. Verfuerth, R. Pettengell, J. C. W. Marsh, et al.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
Blood, October 1, 2000; 96(7): 2419 - 2425.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. Childs, A. Chernoff, N. Contentin, E. Bahceci, D. Schrump, S. Leitman, E. J. Read, J. Tisdale, C. Dunbar, W. M. Linehan, et al.
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
N. Engl. J. Med., September 14, 2000; 343(11): 750 - 758.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pediatric Oncology NursingHome page
C. L. Rossetto and J. E. McMahon
Current and Future Trends in Transfusion Therapy
Journal of Pediatric Oncology Nursing, July 1, 2000; 17(3): 160 - 173.
[Abstract] [PDF]


Home page
BloodHome page
C. Craddock, R. M. Szydlo, J. P. Klein, F. Dazzi, E. Olavarria, F. van Rhee, C. Pocock, K. Cwynarski, J. F. Apperley, and J. M. Goldman
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
Blood, July 1, 2000; 96(1): 86 - 90.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Verfuerth, K. Peggs, P. Vyas, L. Barnett, R. J. O'Reilly, and S. Mackinnon
Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire
Blood, June 15, 2000; 95(12): 3990 - 3995.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. R. Bishop, S. R. Tarantolo, Z. S. Pavletic, J. C. Lynch, M. E. Morris, D. Zacharias, J. O. Armitage, and A. Kessinger
Filgrastim as an Alternative to Donor Leukocyte Infusion for Relapse After Allogeneic Stem-Cell Transplantation
J. Clin. Oncol., June 11, 2000; 18(11): 2269 - 2272.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Guglielmi, W. Arcese, J. Hermans, A. Bacigalupo, G. Bandini, D. Bunjes, E. Carreras, A. Devergie, F. Frassoni, J. Goldman, et al.
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis
Blood, June 1, 2000; 95(11): 3328 - 3334.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C.-M. Seong, S. Giralt, H. Kantarjian, J. Xu, J. Swantkowski, K. Hayes, A. B. Glassman, I. Khouri, M. Korbling, P. Thall, et al.
Early Detection of Relapse by Hypermetaphase Fluorescence In Situ Hybridization After Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia
J. Clin. Oncol., May 9, 2000; 18(9): 1831 - 1836.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Gao, I. Bellantuono, A. Elsasser, S. B. Marley, M. Y. Gordon, J. M. Goldman, and H. J. Stauss
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
Blood, April 1, 2000; 95(7): 2198 - 2203.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Pinilla-Ibarz, K. Cathcart, T. Korontsvit, S. Soignet, M. Bocchia, J. Caggiano, L. Lai, J. Jimenez, J. Kolitz, and D. A. Scheinberg
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
Blood, March 1, 2000; 95(5): 1781 - 1787.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. L. Porter, R. H. Collins Jr, C. Hardy, N. A. Kernan, W. R. Drobyski, S. Giralt, M. E.D. Flowers, J. Casper, A. Leahey, P. Parker, et al.
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
Blood, February 15, 2000; 95(4): 1214 - 1221.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. J. Link, T. Seregina, A. Traynor, and R. K. Burt
Cellular Suicide Therapy of Malignant Disease
Oncologist, February 1, 2000; 5(1): 68 - 74.
[Abstract] [Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1990 by American Society of Hematology         Online ISSN: 1528-0020